Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 26;15(11):2932.
doi: 10.3390/cancers15112932.

Overview of Molecular Detection Technologies for MET in Lung Cancer

Carina Heydt  1 , Michaela Angelika Ihle  1 , Sabine Merkelbach-Bruse  1
Affiliations
Review

Overview of Molecular Detection Technologies for MET in Lung Cancer

Carina Heydt et al. Cancers (Basel). .

Abstract

MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET proto-oncogene, including MET overexpression, the activation of MET mutations, MET mutations that lead to MET exon 14 skipping, MET gene amplifications, and MET fusions, are known to be primary and secondary oncogenic drivers in cancer; these aberrations have evolved as predictive biomarkers in clinical diagnostics. Thus, the detection of all known MET aberrations in daily clinical care is essential. In this review, current molecular technologies for the detection of the different MET aberrations are highlighted, including the benefits and drawbacks. In the future, another focus will be on the standardization of detection technologies for the delivery of reliable, quick, and affordable tests in clinical molecular diagnostics.

Keywords: MET; MET exon 14 skipping mutation; MET fusion; MET gene amplification; NSCLC.

PubMed Disclaimer

Conflict of interest statement

Carina Heydt has received honoraria from AstraZeneca, BMS, Illumina, and Molecular Health; Michaela Angelika Ihle has received honoraria from AstraZeneca, BMS, Novartis, and Merck; Sabine Merkelbach-Bruse has received honoraria and travel support from Amgen, AstraZeneca, Bayer, BMS, GSK, Janssen, Merck, MSD, Molecular Health, Novartis, Pfizer, QuIP, Roche, and Targos.

Figures

Figure 1
Figure 1
Schematic representation of MET aberrations in the MET receptor.
Figure 2
Figure 2
Clinical utility of the analysis of tumor material in molecular pathology diagnostics over time.
See this image and copyright information in PMC

References

    1. Fujino T., Suda K., Mitsudomi T. Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. Lung Cancer. 2021;12:35–50. doi: 10.2147/LCTT.S269307. - DOI - PMC - PubMed
    1. Gelsomino F., Rossi G., Tiseo M. MET and Small-Cell Lung Cancer. Cancers. 2014;6:2100–2115. doi: 10.3390/cancers6042100. - DOI - PMC - PubMed
    1. Guo R., Luo J., Chang J., Rekhtman N., Arcila M., Drilon A. MET-dependent solid tumours-molecular diagnosis and targeted therapy. Nat. Rev. Clin. Oncol. 2020;17:569–587. doi: 10.1038/s41571-020-0377-z. - DOI - PMC - PubMed
    1. Lee M., Jain P., Wang F., Ma P.C., Borczuk A., Halmos B. MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies. Expert Opin. Targets. 2021;25:249–268. doi: 10.1080/14728222.2021.1925648. - DOI - PubMed
    1. Jørgensen J.T., Mollerup J. Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. Cancers. 2022;14:2150. doi: 10.3390/cancers14092150. - DOI - PMC - PubMed

LinkOut - more resources